Streetbeat News

BWVI

Blue Water Ventures International Inc

Employees

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

The World Health Organization (WHO) has expanded its emergency use list for Mpox diagnostics by adding Cepheid's Xpert Mpox PCR test and Roche's Cobas MPXV assay as PCR-based gold standard options.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 1:25 pm

The WHO Chief, Tedros, announced that Mpox vaccines could be ready for emergency use listing within two weeks, with some vaccines expected to arrive in Congo soon.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 1:57 pm

The WHO has received its first expression of interest for emergency use listing from a Mpox diagnostics manufacturer. WHO officials also discussed polio vaccination plans in Gaza and confirmed applications from Bavarian Nordic and KM Biologics for Mpox vaccines emergency use listing, with 230,000 doses available for Congo.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2024 | 1:55 pm

Zappy Zapolin, a prominent figure in the psychedelics space, discusses his transformative experiences with psychedelics and their therapeutic potential. He has advised companies like KetaMD, acquired by Braxia Scientific (OTC:BRAXF), and co-founded Psycheceutical Bioscience (OTC:BWVI). Zapolin advocates for the legal accessibility of psychedelic medicines to treat conditions like PTSD and addiction.

Portfolio Pulse from Nina Zdinjak

August 13, 2024 | 6:04 pm

In the Benzinga Psychedelics Podcast, Zappy Zapolin discusses the future of psychedelics, highlighting the industry's potential mainstream breakthrough in 2024 with federal legalization of MDMA for PTSD, psychedelics legalization campaigns, and COMPASS Pathways' commercialization. Zapolin, involved with companies like KetaMD (acquired by Braxia Scientific, OTC:BRAXF) and Psycheceutical Bioscience (OTC:BWVI), also launches guided psychedelic retreats, emphasizing the importance of medical supervision in therapy.

Portfolio Pulse from Lara Goldstein

February 29, 2024 | 4:04 pm

Psycheceutical Bioscience, Inc (OTCPK: BWVI) is conducting trials in Australia for its NeuroDirect system, a topical drug delivery method that can deliver psychedelic drugs directly to the brain. The company recently completed dosing the first cohort of subjects in a Phase I clinical trial of its topical ketamine formulation for PTSD. The NeuroDirect system could have applications for a wide range of neuro-related conditions. The patents for NeuroDirect are owned by DEF, LLC and four of them have been licensed to Psycheceutical.

Portfolio Pulse from Maureen Meehan

September 03, 2023 | 6:45 pm

At the MAPS' Psychedelic Science 2023 conference, Zappy Zapolin of Psycheceutical Bioscience Inc (OTC:BWVI) discussed the bright future of psychedelics in mental health, addiction, and peak performance. He emphasized the need for education and guidance in the field, and mentioned Psycheceutical's neurodirect ketamine entering clinical trials in Australia.

Portfolio Pulse from Javier Hasse

June 23, 2023 | 7:36 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.